<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629941</url>
  </required_header>
  <id_info>
    <org_study_id>041-104</org_study_id>
    <secondary_id>P08652</secondary_id>
    <nct_id>NCT00629941</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of AzaSite速 in Subjects With Blepharitis</brief_title>
  <official_title>A Multi-Center, Open-Label Study Evaluating the Cytokine and Eyelid Margin Bacterial Load Levels of Subjects Diagnosed With Chronic Blepharitis Following Dosing With AzaSite速 (Azithromycin Ophthalmic Solution) 1%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of AzaSite速 ophthalmic
      solution, 1% on signs &amp; symptoms of blepharitis and tear cytokine and eyelid bacterial load
      levels
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in clinical signs and symptoms associated with blepharitis</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard ocular safety assessments</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tear cytokine and eyelid bacterial load levels</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AzaSite速</intervention_name>
    <description>Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of moderate to severe chronic blepharitis

          -  If female of childbearing potential, are non-pregnant and non-lactating

        Exclusion Criteria:

          -  Had ocular surface surgery (LASIK, refractive, etc.) within the past year

          -  Unwilling to discontinue use of contact lenses during the study

          -  Have glaucoma

          -  Unable or unwilling to withhold the use of lid scrubs during the study

          -  Have a serious systemic disease or uncontrolled medical condition that in the judgment
             of the investigator could confound study assessments or limit compliance

          -  Currently using any preserved topical ocular medications (with the exception of
             unpreserved tear substitutes) at the time of entry into the study or during study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Haque, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Maine Eye Care</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Research Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <disposition_first_submitted>March 24, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 13, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 17, 2009</disposition_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Inspire Pharmaceuticals, Inc.</name_title>
    <organization>sponsor</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

